title: How can prognosis for diabetic ESRD be improved?
abstract: Although the prognosis of patients who have diabetes and are receiving renal replacement therapy has greatly improved, survival and medical rehabilitation rates continue to be significantly worse than those of nondiabetic patients, mainly because of pre-existing severely compromised cardiovascular conditions. In this scenario, the nephrology community had to do its best in order to offer the best treatment options to these patients using a multifaceted approach. The most common RRT modality in patients with diabetes is still hemodialysis, but it gives rise to a number of clinical problems, in particular difficulties in the management of the vascular access and high frequency of intradialytic hypotension. Recent data suggest that efficient high-flux treatments have the potential of improving morbidity and mortality of diabetics with ESRD. Sodium profiling during the dialysis session may be also of importance in reducing intradialytic hypotension and helping in achieving the prescribed body weight. Patients who have diabetes and are on peritoneal dialysis have to face a progressive increase in peritoneal permeability, loss of ultrafiltration, and peritoneal fibrosis, all phenomena being accelerated in patients with diabetes and ultimately leading to an increased technique failure. However, the two dialytic modalities are comparable in terms of outcomes in the short term.
authors.affiliation: Department of Nephrology and Dialysis, Ospedale A. Manzoni, Via dell'Eremo 9, 23900 Lecco, Italy. nefrologia@ospedale.lecco.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Vecchio
authors.forename: Andrea
authors.initials: A
authors.lastname: Cavalli
mesh_terms: D001672:Biocompatible Materials; D002406:Catheterization, Peripheral / Q000379:methods; D003928:Diabetic Nephropathies / Q000628:therapy*; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008567:Membranes, Artificial; D011379:Prognosis; D017582:Renal Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D013997:Time Factors
chemical_list: D001672:Biocompatible Materials; D008567:Membranes, Artificial